跳转至内容
Merck
CN
  • Functional genomics elucidates regulatory mechanisms of Parkinson's disease-associated variants.

Functional genomics elucidates regulatory mechanisms of Parkinson's disease-associated variants.

BMC medicine (2022-02-17)
Rui Chen, Jiewei Liu, Shiwu Li, Xiaoyan Li, Yongxia Huo, Yong-Gang Yao, Xiao Xiao, Ming Li, Xiong-Jian Luo
摘要

Genome-wide association studies (GWASs) have identified multiple risk loci for Parkinson's disease (PD). However, identifying the functional (or potential causal) variants in the reported risk loci and elucidating their roles in PD pathogenesis remain major challenges. To identify the potential causal (or functional) variants in the reported PD risk loci and to elucidate their regulatory mechanisms, we report a functional genomics study of PD. We first integrated chromatin immunoprecipitation sequencing (ChIP-Seq) (from neuronal cells and human brain tissues) data and GWAS-identified single-nucleotide polymorphisms (SNPs) in PD risk loci. We then conducted a series of experiments and analyses to validate the regulatory effects of these (i.e., functional) SNPs, including reporter gene assays, allele-specific expression (ASE), transcription factor (TF) knockdown, CRISPR-Cas9-mediated genome editing, and expression quantitative trait loci (eQTL) analysis. We identified 44 SNPs (from 11 risk loci) affecting the binding of 12 TFs and we validated the regulatory effects of 15 TF binding-disrupting SNPs. In addition, we also identified the potential target genes regulated by these TF binding-disrupting SNPs through eQTL analysis. Finally, we showed that 4 eQTL genes of these TF binding-disrupting SNPs were dysregulated in PD cases compared with controls. Our study systematically reveals the gene regulatory mechanisms of PD risk variants (including widespread disruption of CTCF binding), generates the landscape of potential PD causal variants, and pinpoints promising candidate genes for further functional characterization and drug development.

材料
货号
品牌
产品描述

Sigma-Aldrich
嘌呤霉素,二盐酸盐, Puromycin, Dihydrochloride, CAS 58-58-2, is An aminonucleoside antibiotic that inhibits protein synthesis by blocking the translation step and causes premature release of nascent polypeptide chains.